Emerging evidence suggests that inhibiting CHI3L1 can reduce neuroinflammation and improve cognitive functions in animal models, underscoring its potential as a therapeutic target for CNS disorders [46, 47]. This evidence concerns the gene CHI3L1 and central nervous system disorder.